Tyloxapol

Tyloxapol
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	R05CA01 (WHO) ;
Identifiers
	IUPAC name formaldehyde;oxirane;4-(2,4,4-trimethylpentan-2-yl)phenol;
CAS Number	25301-02-4 ;
PubChem CID	71388;
DrugBank	DB06439 ;
ChemSpider	11052515 ;
UNII	Y27PUL9H56;
KEGG	D03261 ;
ChEMBL	ChEMBL1201548 ;
CompTox Dashboard (EPA)	DTXSID30179950 ;
ECHA InfoCard	100.209.660
Chemical and physical data
Formula	(C15H21O(C2H4O)m)n
Molar mass	variable
	(what is this?) (verify)

Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type. It is used as a surfactant to aid liquefaction and removal of mucopurulent^{[citation needed]} (containing mucus and pus) bronchopulmonary secretions,^[1]^[2] administered by inhalation through a nebulizer^[3] or with a stream of oxygen.

With intraperitoneal injection, tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins. This mechanism is used to induce experimental hyperlipidemia in animals.^[4]

Tyloxapol is the main active ingredient of the medical device Tacholiquin®. Tacholiquin® is an expectorant designated for inhalation and instillation reaching the upper and lower airways. Other brand names of pharmaceutical products containing Tyloxpol are Exosurf and Alevaire.

References

^ Sehgal, S. S.; Ewing, C. K.; Richards, T.; Taeusch, H. W. (1994). "Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: A pilot study". Journal of the National Medical Association. 86 (1): 46–52. PMC 2607653. PMID 8151722.
^ Rubin, B. K.; Ramirez, O.; King, M. (1992). "Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy". Chest. 101 (4): 1080–1085. doi:10.1378/chest.101.4.1080. PMID 1555424.
^ Drugs.com: Tyloxapol definition
^ Kourounakis, A. P.; Victoratos, P.; Peroulis, N.; Stefanou, N.; Yiangou, M.; Hadjipetrou, L.; Kourounakis, P. N. (2002). "Experimental hyperlipidemia and the effect of NSAIDs". Experimental and molecular pathology. 73 (2): 135–138. doi:10.1006/exmp.2002.2449. PMID 12231215.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

[1] Sehgal, S. S.; Ewing, C. K.; Richards, T.; Taeusch, H. W. (1994). "Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: A pilot study". Journal of the National Medical Association. 86 (1): 46–52. PMC 2607653. PMID 8151722.

[2] Rubin, B. K.; Ramirez, O.; King, M. (1992). "Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy". Chest. 101 (4): 1080–1085. doi:10.1378/chest.101.4.1080. PMID 1555424.

[3] Drugs.com: Tyloxapol definition

[4] Kourounakis, A. P.; Victoratos, P.; Peroulis, N.; Stefanou, N.; Yiangou, M.; Hadjipetrou, L.; Kourounakis, P. N. (2002). "Experimental hyperlipidemia and the effect of NSAIDs". Experimental and molecular pathology. 73 (2): 135–138. doi:10.1006/exmp.2002.2449. PMID 12231215.

[1]

[2]

[3]

[4]